Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years
Conditions
Interventions
SARS-CoV-2 Vaccine (Vero Cells), Inactivated
Placebo
Locations
1
China
Hunan Provincial Center for Diseases Control and Prevention
Changsha, Hunan, China
Start Date
September 1, 2021
Primary Completion Date
March 1, 2023
Completion Date
April 1, 2023
Last Updated
August 18, 2021
NCT06082518
NCT07221162
NCT06631287
NCT06679140
NCT06417762
NCT03830320
Lead Sponsor
Shenzhen Kangtai Biological Products Co., LTD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions